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Pulmonary embolism (PE) is a common complication in critical ill-ness (1), with a mortality rate of up to 25% (2). Although PE has 
potentially serious consequences, it is often unrecognized in critically 
ill patients. Left undiagnosed, PE in critically ill patients who have 
impaired cardiopulmonary reserve may experience catastrophic conse-
quences (3). In a 25-year longitudinal study, 9% of hospital patients 
had PE at autopsy and, in 84% of these, the diagnosis was missed 
before death (4,5). Even in critically ill patients, PE remains one of the 
most common unsuspected autopsy findings (6).
PE is particularly difficult to diagnose in critically ill patients. 
Diagnosis requires a high index of clinical suspicion (7,8) because 
critically ill patients are usually unable to communicate their symp-
toms due to their underlying condition, pharmacotherapy and mech-
anical ventilation. In addition, signs and symptoms, such as dyspnea, 
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baCKgRounD: Prediction scores for pretest probability of pulmonary 
embolism (PE) validated in outpatient settings are occasionally used in the 
intensive care unit (ICU). 
obJeCtive: To evaluate the correlation of Geneva and Wells scores 
with adjudicated categories of PE in ICU patients.
MethoDs: In a randomized trial of thromboprophylaxis, patients with 
suspected PE were adjudicated as possible, probable or definite PE. Data 
were then retrospectively abstracted for the Geneva Diagnostic PE score, 
Wells, Modified Wells and Simplified Wells Diagnostic scores. The 
chance-corrected agreement between adjudicated categories and each 
score was calculated. ANOVA was used to compare values across the three 
adjudicated PE categories.
Results: Among 70 patients with suspected PE, agreement was 
poor between adjudicated categories and Geneva pretest probabilities 
(kappa=0.01 [95% CI −0.0643 to 0.0941]) or Wells pretest probabili-
ties (kappa=−0.03 [95% CI −0.1462 to 0.0914]). Among four possible, 
16 probable and 50 definite PEs, there were no significant differences in 
Geneva scores (possible = 4.0, probable = 4.7, definite = 4.5; P=0.90), 
Wells scores (possible = 2.8, probable = 4.9, definite = 4.1; P=0.37), 
Modified Wells (possible = 2.0, probable = 3.4, definite = 2.9; P=0.34) or 
Simplified Wells (possible = 1.8, probable = 2.8, definite = 2.4; P=0.30).
ConClusions: Pretest probability scores developed outside the ICU 
do not correlate with adjudicated PE categories in critically ill patients. 
Research is needed to develop prediction scores for this population.
Key Words: Intensive care unit; Prediction models; Pulmonary embolism
les indices de prédiction ne sont pas corrélés avec 
les catégories cliniques d’embolie pulmonaire des 
patients gravement malades
histoRiQue : Les indices de prédiction d’embolie pulmonaire (EP) 
validés en consultations externes avant le test sont parfois utilisés à l’unité 
de soins intensifs (USI).
obJeCtiF : Évaluer la corrélation des indices de Geneva et de Wells avec 
des catégories d’EP attribuées aux patients de l’USI.
MÉthoDologie : Dans un essai aléatoire de thromboprophylaxie, 
les patients ayant une EP présumée ont été classés entre une EP possible, 
probable ou définitive. Les chercheurs ont ensuite rétrospectivement 
extrait les données pour déterminer l’indice diagnostique d’EP de Geneva 
et les indices diagnostiques de Wells, de Wells modifié et de Wells simpli-
fié. Ils ont calculé le consensus corrigé en fonction du hasard entre les 
catégories et chaque indice. Ils ont utilisé l’analyse de variance pour com-
parer les valeurs entre les trois catégories d’EP.
RÉsultats : Chez les 70 patients ayant une EP présumée, on observait 
peu de consensus entre les catégories et les probabilités de Geneva avant le 
test (kappa=0,01 [95 % IC −0,0643 à 0,0941]) ou les probabilités de Wells 
avant le test(kappa=−0,03 [95 % IC −0,1462 à 0,0914]). Entre les quatre 
EP possibles, les 16 probables et les 50 définitives, les chercheurs n’ont 
remarqué aucune différence significative des indices de Geneva (possible = 
4,0, probable = 4,7, définitive = 4,5; P=0,90), des indices de Wells (possi-
ble = 2,8, probable = 4,9, définitive = 4,1; P=0,37), de Wells modifié (pos-
sible = 2,0, probable = 3,4, définitive = 2,9; P=0,34) ou de Wells simplifié 
(possible = 1,8, probable = 2,8, définitive = 2,4; P=0,30).
ConClusion : Les indices de probabilité avant le test élaborés à 
l’extérieur de l’USI ne sont pas corrélés avec les catégories d’EP des 
patients gravement malades. Des recherches s’imposent pour élaborer des 
indices de prédiction au sein de cette population.
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tachycardia, hypoxemia and hypotension, which are suggestive of PE 
in nonintensive care unit (ICU) settings, are considerably more com-
mon in the ICU setting and attributable to many other factors. Tests 
that may be suggestive of physiological alterations compatible with PE 
(eg, decreased oxygen saturation, increased plasma troponin concen-
tration) are often nonspecifically abnormal in critically ill patients.  
Clinical decision rules (9-13) are used in medicine to provide pre-
test probabilities and guide decision making. Due to the silent nature 
of some PEs (14), simple, objective diagnostic scoring systems could be 
helpful in diagnosing PE. These prediction scores are often detailed in 
the chart or used in conversation with the ICU team because they are 
the only scores developed for PE. These scores have utility in patient 
populations in which they were developed and validated, in addition 
to other patient groups. Although these PE scores have been 
developed and tested in the emergency department, they have not 
been validated in the ICU setting. We aimed to establish whether 
these PE scores have discriminative power in the critically ill popula-
tion. The objective of the present study was to evaluate whether two 
diagnostic PE scores – the Geneva and Wells scores – were useful in 
distinguishing critically ill patients who had possible, probable or def-
inite PE according to clinical adjudication.  
MethoDs
The present preplanned study was conducted using the database from 
a recent international trial (Prophylaxis of Thromboembolism in 
Critical Care [PROTECT] ; Clinicaltrials.gov number: NCT00182143) 
that compared the low-molecular weight heparin (LMWH) daltep-
arin, and unfractionated heparin (UFH) for thromboprophyaxis in 
3746 medical-surgical ICU patients (15). The study was conceived as 
a project under the ‘PE-METRICS’ program, which was designed to 
use the infrastructure of the PROTECT trial to understand the meth-
odology, epidemiology and treatment of PE in critically ill patients. 
The PE-METRICS grant was submitted while PROTECT was enrol-
ling patients to conduct work related to PE after the main publication. 
This was a peer-review, funded research program. Ethics approval was 
obtained as part of the PROTECT publication.  
In PROTECT, patients were routinely screened with twice-weekly 
compression ultrasound for proximal leg deep vein thrombosis (DVT). 
However, PE detection did not involve screening. Patients who 
developed suspected PE were investigated and managed by the local 
ICU team using a predetermined diagnostic algorithm. First, these 
patients underwent bilateral leg ultrasound. Then, chest computed tom-
ography pulmonary angiogram was performed in the 70 patients who did 
not have contraindications to this procedure. Thereafter, four mem-
bers of a central adjudication committee (DC, MM, SM and RH) each 
independently adjudicated, using trial forms and the patient’s chart, all 
cases of suspected PE. Adjudicators resolved disagreements by consen-
sus. PE events were adjudicated as possible, probable or definite, and 
are defined in Table 1. Definite PE was defined by a clearly positive 
test (such as characteristic intraluminal filling defect on chest com-
puted tomography or high-probability ventilation-perfusion scan). 
Probable PE was defined by a high clinical suspicion (moderate or high 
pretest probability) and either a nondiagnostic test for PE or no test for 
PE. Possible PE was defined as low clinical suspicion (low pretest prob-
ability) and a nondiagnostic test for PE. ‘No test for PE’ is not part of 
the definition of a possible PE because the clinical concern had to be 
sufficient to order a test unless the patient was moribund or preter-
minal. ‘No PE’ was defined as either no test for PE or a clearly negative 
test for PE. A nondiagnostic test was defined as an inconclusive test for 
PE and did not include negative tests (15). In the present study, 
patients who had clinically suspected prevalent PE (diagnosed within 
72 h of ICU admission) or incident PE (diagnosed >72 h following 
ICU admission) were included. 
geneva and Wells scores
Appendix Tables 1 to 4 summarize the four scoring systems (9-13) used 
in the present study. The maximum Geneva score of 16 corresponds to 
a pretest probability of 81%; a score of ≤4 corresponds to a pretest 
probability of 10.3% (9,11). The Wells PE Diagnostic score has a max-
imum score of 12.5, which corresponds to a pretest probability of 
40.6%; a score of ≤4 corresponds to a pretest probability of <7.8% 
(10). The Modified Wells PE Diagnostic score (13) has a maximum 
score of 9; a score of ≤4 corresponds to a pretest probability of 6% and 
a score of >4 corresponds to a pretest probability of 78%. The 
Simplified Wells PE Diagnostic score (12) has a maximum score of 7, 
which corresponds to a pretest probability of 62%; the minimum score 
of 1 corresponds to a pretest probability of 12%. 
Pilot exercise
A pilot exercise was conducted to examine and optimize interobserver 
rater agreement in preparation for the full study. In duplicate and 
independently, two research personnel (CK and MD) retrospectively 
abstracted data relevant to the scoring systems from medical records in 
a computerized ICU clinical information system (CareVue, Philips 
Inc, USA), written clinical notes, laboratory and other test results 
from the day that PE was suspected (within 12 h). Using pretested 
forms and an implementation manual, the two blinded raters abstracted 
data regarding signs and symptoms of PE, and data to calculate diag-
nostic score in a reliability and calibration exercise on one trial 
patient; subsequently, two blinded raters abstracted 18 items (six 
symptoms, eight signs, two tests and two scores) from the medical 
records of four trial patients. These individual variables were defined 
as per previous studies (16): six symptoms (dyspnea, pleuritic chest 
pain, substernal chest pain, cough, hemoptysis and syncope), eight 
signs (fever >38°C, tachypnea with respiratory rate >30 breaths/min, 
tachycardia [heart rate >100 beats/min], hypotension [systolic blood 
pressure <100 mmHg], central cyanosis, oxygen saturation <90%, 
physical signs of DVT such as calf pain, unilateral calf swelling or pain 
on flexion, and cardiopulmonary arrest) and two test results (arterial 
partial pressure of oxygen and echocardiographic findings of right heart 
strain). Data were also abstracted to calculate the Geneva Diagnostic 
score and the original Wells score. Chance-corrected agreement (using 
the original interpretation by Fleiss [17]) was calculated between two 
raters’ measures of each dichotomous variable and each score.
Chance-corrected agreement values on the initial pilot exercise for 
symptoms were: dyspnea κ=0.82, pleuritic chest pain κ=0.97, subster-
nal chest pain κ=0.90, cough κ=0.85, syncope κ=0.85; for signs: fever 
κ=0.71, tachypnea κ=0.78, tachycardia κ=0.60, hypotension κ=0.95, 
hemoptysis κ=0.85, cyanosis κ=0.59, desaturation κ=0.91, physical 
signs of DVT κ=0.87, cardiopulmonary arrest κ=0.88; and for test 
results: arterial blood gas PO2 κ=0.70, echocardiographic signs of right 
heart strain κ=0.90. For PE diagnostic scores, agreement was: Geneva 
diagnostic score κ=0.53, original Wells score κ=0.71 (Table 2).
TablE 1
Definitions of pulmonary embolism (PE) adjudication 
categories
PE category Definition
Possible Possible PE was defined as low clinical suspicion (low 
pretest probability) and a nondiagnostic test for PE. ‘No 
test for PE’ is not part of the definition of a possible PE 
because the clinical concern had to be sufficient to order 
a test unless the patient was moribund or preterminal
Probable Probable PE was defined by a high clinical suspicion 
(moderate or high pretest probability by the adjudication 
committee) and either a nondiagnostic test for PE or no 
test for PE
Definite Definite PE was defined by a positive test (such as 
characteristic intraluminal filling defect on computed 
tomography pulmonary angiogram or high probability 
ventilation-perfusion scan)
PE adjudication categories used by adjudication committee defined in the 
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial (15)
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Case report forms were distributed to research personnel in 67 cen-
tres that participated in the PROTECT trial (15). Blinded to study 
drug and PE adjudication status, research personnel (physicians or 
research coordinators) at each centre retrospectively abstracted data to 
calculate four scores: the Geneva score, original Wells score, Modified 
Wells score and Simplified Wells score. The research personnel who 
abstracted the data were asked to tabulate the points for each score 
based on interpreting the physicians’ notes, nurses’ notes, laboratory or 
other test values. The attempt was made to make assessments and 
assign numerical points as per clinical practice.  
analysis
To examine the relationship among the three adjudicated categories of 
possible, probable and definite PE, and each of the low, intermediate 
and high pretest probability categories of PE on the Geneva and Wells 
scores, respectively, chance-corrected agreement was calculated using 
kappa and its original interpretation by Fleiss (17). ANOVA was used 
to examine the association between clinically adjudicated categories 
of PE and values for each of the four diagnostic scores. P<0.05 indi-
cated that a diagnostic score was significantly different across three 
adjudicated categories of possible, probable and definite PE. 
Results
There were 3746 patients included in the PROTECT trial. There 
were 70 patients in the final study including the five pilot patients, 
reflecting all 70 patients who were adjudicated for PE in the 
PROTECT trial; these patients were cared for in 30 of the 67 par-
ticipating centres (Table 3). This yields an incidence of 1.9% (70 of 
3746) of patients who were adjudicated for PE. Of the 70 PEs in the 
present study, 10 were prevalent and 60 were incident. Of 70 patients, 
four were adjudicated as ‘possible PE’, 16 as ‘probable PE’ and 50 as 
‘definite PE’. Agreement was poor between adjudicated categories 
of PE and both Geneva score pretest probabilities (κ=0.01 [95% CI 
−0.0643 to 0.0941]) and Wells score pretest probabilities (κ=−0.03 
[95% CI −0.1462 to 0.0914]). Across four patients who had possible, 
16 patients who had probable and 50 patients who had definite PE, 
there were no significant differences in total Geneva scores (possible = 
4.0, probable = 4.7, definite = 4.5; P=0.90), total original Wells scores 
(possible = 2.8, probable = 4.9, definite = 4.1; P=0.37), Modified 
Wells scores (possible = 2.0, probable = 3.4, definite = 2.9; P=0.34) or 
Simplified Wells scores (possible = 1.8, probable = 2.8, definite = 2.4; 
P=0.30) (Table 4).
DisCussion
Among 70 patients with a clinical suspicion of PE adjudicated in the 
PROTECT trial (15), agreement was poor among adjudicated categor-
ies of PE and each of the Geneva score and three Wells scores. Across 
TablE 2
Pilot study: agreement scores
Symptom κ Signs κ
Dyspnea 0.82 Fever >38°C 0.71 
Pleuritic chest pain 0.97 Respiratory rate >30 breaths/min 0.78 
Substernal chest pain 0.90 Heart rate >100 beats/min 0.60
Cough 0.85 Systolic blood pressure <100 mmHg 0.95 
Syncope 0.85 Cyanosis 0.59 
Desaturation <90% 0.91 
Physical signs of deep vein thrombosis 0.87 
Cardiopulmonary arrest 0.88 
Hemoptysis 0.85 
Test results κ Diagnostic models κ
ABG PO2 criteria 0.70 Wells 0.71 
Echo criteria 0.90 Geneva 0.53 
Inter-rater agreement (between two raters) for signs, symptoms and test 
results for pulmonary embolism in five pilot study patients. Kappa values are 
presented, indicating chance-corrected agreement between two raters. ABG 
Arterial blood gas; Echo Echocardiography
TablE 3
Demographic and clinical characteristics of patients adjudicated for pulmonary embolism (PE)
Characteristic Possible PE Probable PE Definite PE P
Patients, n 4 16 50 –
Patient demographics
   Age, years, mean ± SD 59.9±22.8 56.7±14.7 59.2±16.8 0.86
   Female sex, n (%) 0 (0.0) 6 (37.5) 16 (32.0) 0.40
   Body mass index, kg/m2, mean ± SD 22.9±4.0 34.4±10.7 29.8±8.5 0.05
   Medical admission, n (%) 4 (100.0) 13 (81.3) 40 (80.0) >0.99
   APACHE II score, mean ± SD 21.0±6.1 22.5±7.6 21.2±5.9 0.77
Comorbid illness at baseline, n (%)
   History of or current malignancy 1 (25.0) 0 (0.0) 4 (8.0) 0.22
   Heart failure 0 (0.0) 0 (0.0) 2 (4.0) >0.99
   Personal history of venous thromboembolism 0 (0.0) 1 (6.3) 3 (6.0) >0.99
   Family history of venous thromboembolism 0 (0.0) 0 (0.0) 0 (0.0) –
   End-stage renal disease (dialysis dependent) 0 (0.0) 0 (0.0) 0 (0.0) –
   Prevalent PE* 1 (25.0) 0 (0.0) 10 (20.0) 0.10
Baseline life support, n (%)
   Vasopressor dependent 1 (25.0) 8 (50.0) 27 (54.0) 0.65
   Mechanically ventilated 4 (100.0) 16 (100.0) 49 (98.0) >0.99
*Diagnosed before intensive care unit admission. APACHE Acute Physiology and Chronic Health Evaluation
TablE 4
Pretest probability scores of published prediction models 
(Geneva, Wells, Modified Wells and Simplified Wells score) 












Geneva score 4.0±3.5 4.7±2.8 4.5±2.8 0.90
Original Wells 2.8±1.0 4.9±3.4 4.1±2.8 0.37
Modified Wells 2.0±0.8 3.4±2.4 2.9±1.9 0.34
Simplified Wells 1.8±0.5 2.8±1.7 2.4±1.3 0.30
Data presented as mean ± SD unless otherwise indicated. See Appendix 
Tables 1 to 4 for the prediction models. PROTECT Prophylaxis of 
Thromboembolism in Critical Care trial
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the three adjudicated categories of PE, there were no significant differ-
ences in total Geneva scores, Wells scores, Modified Wells scores or 
Simplified Wells scores. We conclude that many physiological vari-
ables used in these models, shown to be valuable in the ambulatory 
setting, are of questionable utility when applied to intubated, critically 
ill patients.  
Two possible explanations for the poor agreement among adjudi-
cated categories and prediction scores relate to the population we stud-
ied and the quality of information in the medical charts. Regarding 
the first explanation, some of the variables required to calculate these 
scores cannot be discerned in critically ill patients (eg, dyspnea) and 
are, therefore, nondiscriminatory. All patients in PROTECT were 
considered to be ‘at risk for’ DVT and PE. It is possible that the inci-
dence of venous thromboembolism in this trial could be decreased as 
a consequence of universal prophylaxis with either UFH or LMWH. 
Furthermore, it is possible that patients receiving thromboprophylaxis 
may have different signs and symptoms of PE than patients not receiv-
ing prophylaxis, although, to our knowledge, this has not been studied. 
Bahia and Albert (13) demonstrated that these clinical scores accur-
ately predict PE in prophylaxed hospitalized patients. There have been 
no studies in the literature that document the utility of these scores in 
thromboprophylaxed critically ill patients.
Regarding the issue of information quality, the original data for this 
substudy, and the original trial data collected by research coordinators 
on which the adjudication was based, were from patient medical rec-
ords, which are known in both in paper and electronic formats to 
contain errors of over- (18) and under- (19) documentation on the 
part of nurses (20), trainees (21,22) and staff physicians (23). In other 
words, some components of the scoring systems may be too challen-
ging to detect in ICU patients, whereas other predictor variables may 
be present or absent, but the information may not be recorded in the 
medical charts.  
Strengths of the present study include the development, testing 
and refinement of data abstraction tools in a pilot exercise that docu-
mented excellent inter-rater reliability before starting the full study. 
To avoid ascertainment bias, data for the scoring systems were 
abstracted blinded to study drug, participating centre and adjudicated 
outcome. Similarly, the original PE events were adjudicated in quad-
ruplicate, blinded to study drug, participating centre and other adjudi-
cator assessments. Given the lack of previous evidence to evaluate 
well-known scoring systems for the diagnosis of PE in critically ill 
patients, we designed the present study a priori to examine the utility 
of these diagnostic scores in the ICU setting.
Limitations to the present study include the relatively small num-
ber of patients with PE. Because this thromboprophylaxis trial did not 
protocolize screening for PE, as per usual practice, not all patients 
underwent the same testing to diagnose PE (15). We did not compare 
scores in patients with suspected PE, but were subsequently proven not 
to have PE based on objective testing, or patients with no suspicion 
whatsoever of PE, thereby replicating practice. However, silent PE 
may be relatively common, as suggested in a recent study involving 
176 medical-surgical ventilated ICU patients requiring thoracic 
computed tomography. In this cohort, 33 (18.7%) had PE, including 
20 (61%) with no clinical suspicion (24). Unlike some patients stud-
ied in the original prediction score studies, ICU patients in the present 
study were all receiving either UFH or LMWH thromboprophylaxis 
and had poor cardiopulmonary reserve, which may have influenced 
the threshold of concerns when various signs or symptoms were found. 
The original prediction score studies were also not necessarily com-
pleted in thromboprophylaxed patients; however, they have been 
found to be discriminatory in this population (13).
Our findings may not be generalizable to all types of critically ill 
patients (eg, trauma, neurosurgery or cardiac surgery, who were not 
enrolled in the present study).
We did not apply the prediction scores to all patients, including 
those in whom PE was never considered as a clinical problem, as per 
the original score development process. We chose our methods to best 
approximate the use of the prediction scores in some critical care prac-
tices, abstracting data for these scores in patients in whom the clinical 
suspicion of PE existed. 
Developing PE scoring systems in the future would ideally incor-
porate other tests such as troponin, B-type natriuretic peptide values 
or echocardiographic findings. Specifically, elevated troponin levels 
predict short-term mortality as shown in a meta-analysis of 20 studies 
in general hospitalized patients with acute PE and normal blood pres-
sure (OR 5.24 [95% CI 3.28 to 8.38]) (25). Another meta-analysis 
demonstrated higher risk of death associated with specific echocardio-
graphic findings (OR 2.4 [95% CI 1.3 to 4.3[) and elevated B-type 
natriuretic peptide (OR 7.7 [95% CI 2.9 to 20]) in patients with 
hemodynamically stable PE (26).
ConClusion
Pretest probability models developed and validated outside the ICU 
setting do not correlate with clinically suspected PE in the ICU. 
Further clinical research is needed to identify features that help to reli-
ably identify patients with PE in this setting, and to develop a practical 
clinical prediction rule for critically ill patients with suspected PE. 
Ideally, the latter would incorporate a complete spectrum of risk using 
readily available clinical, physiological and laboratory tests. Such new 
prediction models could be of great value to supplement clinical judg-
ment, and aid in more timely identification and appropriate treatment 
of PE and, possibly, improved patient outcomes.  
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Clinical characteristic Point value
Previous PE/DVT 2
Heart rate >100 beats/min 1
Recent surgery 3
Age, years 
   60–79 1
   >80 2
PaCO2, mmHg
   <36 2
   36–39 1
PaO2, mmHg
   <48.7 4
   48.7–59.9 3
   60–71.2 2
   71.3–83.4 1
Plate-like atelectasis on chest radiograph 1
Elevated hemidiaphragm on chest radiograph 1
DVT Deep vein thrombosis; PaCO2 Partial pressure of carbon dixide; PaO2 
Partial pressure of oxygen; PE Pulmonary embolism
aPPEnDIx TablE 2
Original Wells score
Clinical characteristics Point value
Clinical signs of DVT 3





Alternative diagnosis less likely 3
DVT Deep vein thrombosis; PE Pulmonary embolism
aPPEnDIx TablE 3
Simplified Wells score
Clinical characteristics Point value
Clinical signs of DVT 1





Alternative diagnosis less likely 1
DVT Deep vein thrombosis; PE Pulmonary embolism
aPPenDiXes
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aPPEnDIx TablE 4
Modified Wells score
Clinical characteristics Point value
Clinical signs of DVT 3









DVT Deep vein thrombosis; PE Pulmonary embolism
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